Pancreatic Cancer Research

ResearcherUniversity of Maryland, BaltimoreActive in the last 2 years

S. Perwez Hussain

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2294-522X; OpenAlex author ID A5084852606. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 16)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 1 paper · 2016: 4 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 21

  1. Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clini… Last author DOI 10.1016/j.pharmthera.2025.108946↗
  2. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. Last author DOI 10.1002/ijc.34960↗
  3. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. Last author DOI 10.1093/carcin/bgae011↗
  4. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Last author DOI 10.1093/carcin/bgae025↗
  5. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Last author DOI 10.1093/carcin/bgae056↗
  6. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer. Last author DOI 10.1016/j.celrep.2023.113434↗
  7. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer. Last author DOI 10.1016/j.trecan.2022.03.004↗
  8. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients. Last author DOI 10.1093/carcin/bgac092↗
  9. NO• /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Last author DOI 10.1002/ijc.32733↗
  10. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. Co-author DOI 10.1084/jem.20190354↗
  11. NO• and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. First author DOI 10.1089/ars.2016.6809↗
  12. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3481-4↗
  13. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Last author DOI 10.1158/0008-5472.can-15-2841↗
  14. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-16-0511↗
  15. Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Last author DOI 10.18632/oncotarget.10323↗
  16. Pancreatic Cancer: Current Progress and Future Challenges. Co-author DOI 10.7150/ijbs.14950↗
  17. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression. Co-author DOI 10.1038/nm.3957↗
  18. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pa… Last author DOI 10.1002/ijc.27736↗
  19. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Last author DOI 10.1158/0008-5472.can-13-0362↗
  20. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-13-0209↗
  21. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0031507↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuuki Ohara · 8 shared papers, 2022–2026 · strength 1.67
  2. Nader N Hanna · 14 shared papers, 2012–2024 · strength 1.39
  3. Jochen Gaedcke · 14 shared papers, 2012–2024 · strength 1.39
  4. Azadeh Azizian · 7 shared papers, 2020–2024 · strength 1.12
  5. Paloma Moreno · 5 shared papers, 2023–2026 · strength 1.10
  6. Michael B. Ghadimi · 6 shared papers, 2013–2024 · strength 0.93
  7. Shouhui Yang · 7 shared papers, 2016–2024 · strength 0.71
  8. S. S. Yang · 3 shared papers, 2024 · strength 0.56
  9. Β. Michael Ghadimi · 9 shared papers, 2012–2022 · strength 0.49
  10. Jian Wang · 5 shared papers, 2016–2020 · strength 0.39
  11. H. Richard Alexander · 8 shared papers, 2012–2020 · strength 0.36
  12. Matthias M. Gaida · 5 shared papers, 2015–2020 · strength 0.29
  13. Lin Zhang · 1 shared paper, 2024 · strength 0.18
  14. Jianjun Gao · 1 shared paper, 2024 · strength 0.18
  15. Subrata Sen · 1 shared paper, 2024 · strength 0.18
  16. Nagireddy Putluri · 1 shared paper, 2024 · strength 0.18
  17. Dong Ho Lee · 3 shared papers, 2012–2020 · strength 0.17
  18. Anirban Maitra · 4 shared papers, 2012–2020 · strength 0.17
  19. Lin Zhang · 1 shared paper, 2022 · strength 0.13
  20. Geng Zhang · 4 shared papers, 2012–2013 · strength 0.12
  21. Naotake Funamizu · 3 shared papers, 2012–2016 · strength 0.10
  22. Limin Wang · 1 shared paper, 2020 · strength 0.09
  23. Sulagna Banerjee · 1 shared paper, 2020 · strength 0.08
  24. Yu Zhang · 1 shared paper, 2020 · strength 0.08
  25. Huamin Wang · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.